Field Guide · Deconstructed

Methylene blue.
The 150-year-old dye on the kill-menu.

An old textile dye that became one of medicine’s oldest drugs — and lately a fixture in the Lyme/Bartonella world for biofilm, persisters, and tired mitochondria. Here are the facts: what it actually does at low dose, the real lab evidence (and where it runs out), how to access the right grade, how it’s dosed, and — the part that matters most for PANS kids — the serotonin-syndrome interaction with SSRIs, and how you make it stop. Read the safety section first.

I walked this part of the labyrinth myself — knocked on the doors, read the research, and came back with the map. You don’t have to find the way out alone.

The two rules that come before everything

1. If your child is on an SSRI or SNRI, methylene blue is a serotonin-syndrome risk — do not combine them casually. Methylene blue is a potent MAO inhibitor. Many PANS kids are on an antidepressant; this is the single most important fact on this page. The FDA has formally warned about it. Details and the “how to make it stop” plan are below.

2. Use pharmaceutical USP grade only — never aquarium or industrial methylene blue. The cheap aquarium/lab versions can carry arsenic, lead, and other heavy metals that fish tolerate and children must never ingest. This is a real, documented danger, not a marketing line.

  • Screen for G6PD deficiency first — in G6PD-deficient kids, methylene blue can trigger hemolysis (red-cell breakdown). It is contraindicated there.
  • Only under a knowledgeable prescriber — this is a real drug with real interactions, not a supplement to self-experiment with on a child.
  • It will turn urine (and sometimes the whites of the eyes, stool, and skin) blue-green. That part is harmless — but tell the family so no one panics.

What it is

Methylene blue is one of the oldest synthetic drugs in medicine. First made in 1876 as a textile dye, it became a medication soon after and has been on the World Health Organization’s List of Essential Medicines for decades. Its one FDA-approved use is treating methemoglobinemia — a condition where hemoglobin can’t carry oxygen — given intravenously at 1–2 mg/kg. Everything else it’s used for is off-label.

The interesting part for chronic illness is what it does at low dose, where its pharmacology is completely different from the high-dose antidote use:

The mental model: at high dose it’s an emergency antidote (methemoglobinemia). At low dose it’s a small molecule that touches three things PANS families care about at once — the energy engine (mitochondria), stubborn infections (biofilm/persisters), and inflammation/redox. That triple overlap is the appeal. The catch is its MAOI behavior, which collides with SSRIs. Methylene Blue, StatPearls · Methylene Blue: Revisited, 2011

The PANS / Lyme angle

In the chronic-Lyme and Bartonella world, methylene blue earns its place for two reasons: it appears to hit the hidden forms of infection that standard antibiotics miss, and it supports mitochondria in kids whose energy systems are wrecked by chronic infection. Here’s the honest level of that evidence.

The lab evidence against Bartonella and Borrelia persisters is genuinely interesting

  • In Zhang-group in-vitro work, methylene blue was among the most active agents against biofilm Bartonella henselae — and antibiotic combinations like azithromycin + methylene blue and rifampin + methylene blue completely eradicated biofilm B. henselae after 6 days, where single drugs left survivors. A single exposure dropped stationary-phase Bartonella by roughly 75–84%. Zhang group, biofilm B. henselae in vitro
  • Against stationary-phase (persister-like) Borrelia burgdorferi, methylene blue showed activity in the Johns Hopkins persister screens — the same body of work that flagged Cryptolepis and Japanese knotweed. Feng & Zhang persister screening, 2020

But be honest: this is lab-dish data, not human proof

Those striking numbers are in vitro — bacteria in a dish, not children. There are no controlled human trials showing methylene blue cures Lyme, Bartonella, or PANS, and nothing has been studied for PANS specifically. The clinical use rests on that lab signal plus Lyme-clinician experience (Horowitz and others use it inside dapsone-combination protocols). It’s reasonable to explore — labeled as emerging, not established.

Where it fits on the kill-menu: methylene blue sits in the “refractory / what hasn’t been tried” tier — for a chronic Bartonella or biofilm picture, or for genuine mitochondrial drag, layered in with a knowledgeable prescriber. It is most compelling combined (the biofilm eradication in the lab was the combinations, not methylene blue alone), and most dangerous combined with an SSRI.

Choose your path

This decision tree is only for a child cleared on the two rules above. Start at the top and follow your situation; each step is backed by the evidence on this page. Tap to open.

1 · Is your child on an SSRI or SNRI?

YesSTOP and route to the prescriber. Methylene blue + an SSRI/SNRI is a serotonin-syndrome risk. This is not a do-it-yourself situation — the medication must be managed (tapered/timed) by the prescribing clinician first.
No / off serotonergic meds → you may continue ↓

2 · Has G6PD been checked?

Not testedscreen for G6PD deficiency first. In G6PD-deficient kids methylene blue can cause hemolysis — it’s contraindicated. Normal → continue ↓

3 · Get the right product, with a prescriber.

Pharmaceutical USP grade only — from a compounding pharmacy on a prescriber’s order. Never aquarium/industrial. Jump to how to access.

4 · Start low — and know the antidote BEFORE the first dose.

Lowest reasonable weight-based dose, with a provider, one variable at a time. Low dose is the antioxidant zone; pushing high flips it pro-oxidant. Know your stop plan first. Jump to dosing + the antidote.

5 · Watch for serotonin-syndrome signs — and stop the right way.

Agitation, confusion, rapid heartbeat, high temperature, sweating, tremor/twitching, rigiditythis is a medical emergency — stop the methylene blue and seek care immediately. Improving / steady → continue the schedule and reassess on the data. Jump to the antidote.

This is a lot to weigh — and you don’t have to weigh it alone. Minta has all of this synthesized. She’ll look at your child — including every medication they’re on — tell you honestly whether methylene blue even belongs on your table, flag the SSRI and G6PD landmines, and if it’s reasonable, help you frame the grade, the start-low dose, and the stop plan for your prescriber. Let Minta do this with you →

How & where to access it

This is the part that quietly decides safety. Methylene blue is cheap and easy to buy in the wrong form — and the wrong form can poison a child. For a kid, there is exactly one acceptable path: pharmaceutical USP grade, on a prescriber’s order, usually from a compounding pharmacy.

SourceWhat it isThe honest note
Compounding pharmacy (on prescription)A prescriber (LLMD / integrative or functional MD) writes for USP pharmaceutical-grade methylene blue — often compounded capsules or an oral solution at a precise low dose.The only route Plan B would put near a child. Dose is controlled, grade is verified, and a clinician is steering the SSRI/G6PD checks.
Pharmaceutical USP-grade supplier≥99% purity, heavy metals below trace limits, with a certificate of analysis from independent lab testing.Verify the certificate of analysis and USP grade. Still best obtained through a prescriber for a child.
Aquarium / lab / industrial gradeSold cheaply for fish tanks and lab staining.NEVER ingest — real danger. Can carry arsenic, lead, zinc chloride, and synthesis contaminants (fish tolerate levels children cannot). No certificate of analysis, no purity guarantee.

Say it plainly: the price gap between aquarium-grade and pharmaceutical-grade methylene blue is the price of the heavy-metal filtration. The cheap stuff is cheap because the contaminants were never removed. If a vendor can’t show you a USP certificate of analysis, it does not go in a child.

Heavy metals: reagent vs USP grade · Methylene Blue, StatPearls

How it’s dosed

Read this as “what’s typically used,” not a prescription. There is no FDA-approved low-dose pediatric protocol for chronic infection or mitochondrial support — the methemoglobinemia dose (1–2 mg/kg IV) is a different, far higher use. For the low-dose use, the rule holds harder than anywhere: start low, go slow, weight-based, one new thing at a time, with a prescriber, off SSRIs.

UseTypical rangeNotes
Low-dose (mito / off-label chronic infection)Often well under 1 mg/kg/day — many adult protocols sit in the 0.5–2 mg/kg/day band, dosed at fractions for sensitive individuals; pediatric use is weight-based and started far lower.This is the antioxidant zone. Stay low — the dose-response is biphasic, so high dose flips pro-oxidant. Titrate up only as tolerated.
FDA-approved (methemoglobinemia)1–2 mg/kg IV, in an acute hospital setting.A different use entirely — emergency antidote, not a chronic-illness protocol. Listed only so the two aren’t confused.

The pattern to notice: the whole reason low-dose works as support is that it stays in the antioxidant/electron-cycling zone. Climb the dose and it becomes a pro-oxidant and raises the methemoglobin/serotonin risk — the same molecule, opposite effect. For a child the steering wheel is “lowest effective dose, titrated by a prescriber.” Anchor it to a real reason to use it (a confirmed Bartonella/biofilm picture or documented mito issue), not a hunch. Methylene Blue: Revisited (biphasic dose-response, low-dose pharmacology)

The big risks & the antidote — know them before you start

This is the part that matters most. Methylene blue is a real drug with two interactions that can hurt a child, and one nuisance that scares families. You do not begin until you can answer: “If this goes wrong, exactly how do I make it stop?”

RiskWhyHow you make it stop
Serotonin syndrome (the big one)Methylene blue is a potent reversible MAO-A inhibitor — roughly 100× stronger than moclobemide at low dose. Combined with an SSRI/SNRI it can drive serotonin dangerously high, even from a single dose. Many PANS kids are on an SSRI — this is the central caution. The FDA formally warned about it in 2011.Prevention is the real answer: the prescriber manages the SSRI/SNRI before exposure (FDA guidance: hold serotonergic drugs ~2–5 weeks before, where clinically appropriate — only the prescriber decides this in a child). If symptoms appear (agitation, fever, rapid heart rate, sweating, tremor, twitching, rigidity, confusion) → stop methylene blue + seek emergency care; serotonin syndrome is managed medically (supportive care, cooling, benzodiazepines, cyproheptadine).
G6PD deficiency → hemolysisMethylene blue’s reduction is NADPH-dependent; in G6PD-deficient kids it can trigger red-cell breakdown (hemolysis) instead of helping.Screen for G6PD before the first dose. If deficient → don’t use it (it’s contraindicated). If it’s ever given and hemolysis appears → stop and manage medically.
Everything turns blueMethylene blue is a dye — urine, sometimes stool, the whites of the eyes, even skin can go blue-green. Harmless, but alarming if no one warned you.No antidote needed — it fades as the drug clears. Just expect it, and don’t mistake it for an emergency.

The rule, stated plainly

  • SSRI/SNRI on board? The antidote is not starting until the prescriber has handled the medication. “We’ll watch for it” is not a plan for serotonin syndrome in a child.
  • G6PD unknown? The antidote is a screening test first. Don’t guess.
  • If serotonin-syndrome signs appear: stop the methylene blue and get emergency medical care — this is treated in a hospital, not at home.
  • You must KNOW your safety plan — SSRI status, G6PD status, prescriber, what the warning signs look like — before the first dose goes in.

Methylene blue & serotonin toxicity (MAO-A inhibition), Br J Pharmacol · APSF: MB & serotonin toxicity (FDA 2011 warning) · Beware methylene blue in G6PD deficiency, Am J Hematol

The evidence — honest level: real lab signal, thin human proof

Here’s the straight version — the established uses are rock-solid, the chronic-infection uses rest on lab data plus clinician experience. Open to it, not sold on it.

What’s genuinely well-established

  • Methemoglobinemia: FDA-approved, decades of use, an emergency antidote. Not in question.
  • The in-vitro antibiofilm / anti-persister data is real: methylene blue (especially combined with azithromycin or rifampin) eradicated biofilm Bartonella henselae in the lab, and showed anti-persister activity against Borrelia. That’s a legitimate scientific basis for the interest — in a dish. Biofilm B. henselae, in vitro
  • The low-dose mitochondrial pharmacology is characterized — the electron-cycling and biphasic redox behavior are well-described in the literature. Methylene Blue: Revisited

Where the proof runs out

  • No human RCTs show methylene blue treats chronic Lyme, Bartonella, or PANS. The clinical use is lab evidence + Lyme-clinician experience (e.g. inside Horowitz’s dapsone combination protocols), not controlled trials.
  • Nothing has been studied for PANS specifically — the rationale is borrowed from the infection and mitochondrial literature.
  • The biofilm wins were combinations, not methylene blue alone — don’t expect monotherapy to do what the pairings did in the dish.

The honest label: established drug, emerging for these uses. The molecule is old and well-understood; its chronic-infection and mito applications are reasonable-to-explore, not proven. A “defensible option on the refractory menu, with eyes open,” not a “this works.”

When to consider it

Who’s not a candidate

  • Kids on an SSRI/SNRI that can’t be safely held/managed — the serotonin-syndrome risk is the hard line.
  • G6PD-deficient kids — contraindicated; hemolysis risk.
  • Anyone who can’t source verified USP grade — if it’s aquarium/industrial, it’s off the table.
  • Anyone without a prescriber willing to monitor — this is not a solo supplement experiment on a child.

How to vet a practitioner

Credentials, polish, and how conventional an approach sounds tell you little about whether a practitioner will help your child — or harm them. What does: their behavior and their incentives. Watch those.

Methylene blue has a buzzy moment — biohacker capsules, “blue tongue” selfies — so hype and credentials tell you nothing. Don’t judge by the buzz; judge the conduct and the incentives.

Red flags

  • Doesn’t ask about SSRIs/SNRIs or G6PD before recommending it for a child — the two safety questions that matter most.
  • Sells you non-pharmaceutical (aquarium/lab) methylene blue for a kid, or can’t produce a USP certificate of analysis.
  • Promises a cure, or pitches it as a stand-alone fix rather than one piece of a sequenced plan.
  • Tells you to stop your other care or dismisses your other doctors.
  • Sells the methylene blue AND the testing AND a supplement stack (the conflict of interest); hides behind “proprietary” and won’t admit the human evidence is thin.

Green flags

  • Asks about every medication first — especially SSRIs/SNRIs — and screens G6PD before starting.
  • Insists on USP pharmaceutical grade and a low, weight-based, titrated dose for a child.
  • Honest that the chronic-infection use is emerging, that the strong data is in-vitro and mostly combinations.
  • Names the risks and the blue urine before you ask; welcomes your other doctors and second opinions and reassesses on how the child is actually doing.

Bottom line

Methylene blue is a 150-year-old, FDA-approved drug with a real low-dose toolkit — mitochondrial electron-cycling, redox antioxidant action, and in-vitro antibiofilm/anti-persister activity that makes it a legitimate “what hasn’t been tried” option for chronic Bartonella, biofilm, and mito drag. But the human proof for those uses is thin — lab data plus clinician experience, no RCTs, nothing in PANS. So it’s a real option on the refractory kill-menu, labeled honestly as emerging. If it’s on your table: off SSRIs (or carefully managed by the prescriber, because of the serotonin-syndrome risk), G6PD-screened, USP pharmaceutical grade only (never aquarium), low and slow, under a knowledgeable prescriber — and expect the blue urine. This is parent education, not medical advice — bring it to your team as questions, not instructions.

How Plan B stays honest

Plan B does not partner with drug companies or doctors, and we never endorse anyone whose healing isn’t verified by families. We show you the options and how to vet them yourself — and we’re building parent verification: look up a practitioner and see real family reviews before you trust them. Universal bad reviews? Skip.

← Back to the Field Guide